Enovis (NYSE:ENOV) Releases Earnings Results, Beats Expectations By $0.14 EPS

Posted by Kyle Jackson on Feb 27th, 2026

Enovis (NYSE:ENOV – Get Free Report) issued its earnings results on Thursday. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14, FiscalAI reports. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%.The firm had revenue of $575.76 million for the quarter, compared to analyst estimates of $584.30 million. During the same quarter in the prior year, the firm earned $0.98 earnings per share. Enovis’s revenue for the quarter was up 2.6% on a year-over-year basis. Enovis updated its FY 2026 guidance to 3.520-3.730 EPS.

Here are the key takeaways from Enovis’ conference call:

The company delivered solid full-year results with 6% organic revenue growth (Recon +8%, PNR +4%), maintained ~18% adjusted EBITDA margins, returned to positive free cash flow of $20M, and guided 2026 revenue of $2.31B–$2.37B with mid-single-digit organic growth and a targeted 25%+ free cash flow conversion for the year.
Management recorded a $501 million non-cash goodwill impairment in Q4, which it says does not affect liquidity, cash flows, or debt covenants but highlights valuation pressures on the business.
Innovation and product momentum accelerated—the company saw 50% more 510(k) clearances than its prior best year, is launching ARVIS with flexible commercial models at AAOS, and reported strong early adoption for Nebula and OrthoDrive alongside double-digit extremities and international Recon growth.
Near-term headwinds remain from about $15M of tariffs and calendar effects (Q4 had four fewer selling days, a ~400bp organic-growth headwind; Q1 2026 also has two fewer days and a high comparable), which constrained quarterly performance and margin flow-through.

Enovis Price Performance

Shares of ENOV stock traded up $3.07 on Thursday, reaching $25.39. 2,700,237 shares of the company were exchanged, compared to its average volume of 1,097,477. Enovis has a 1 year low of $21.00 and a 1 year high of $40.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. The business has a 50-day moving average price of $24.30 and a 200 day moving average price of $28.21. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -1.07 and a beta of 1.52.

Insider Transactions at Enovis

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.70% of the company’s stock.

Institutional Trading of Enovis

A number of institutional investors have recently made changes to their positions in ENOV. Corient Private Wealth LLC raised its stake in Enovis by 540.7% in the 4th quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock valued at $1,470,000 after purchasing an additional 46,568 shares during the last quarter. Front Street Capital Management Inc. raised its position in shares of Enovis by 75.8% in the fourth quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock valued at $9,642,000 after buying an additional 156,069 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Enovis in the fourth quarter valued at about $561,000. Susquehanna Portfolio Strategies LLC lifted its stake in shares of Enovis by 249.9% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock worth $3,756,000 after buying an additional 100,704 shares in the last quarter. Finally, Twinbeech Capital LP acquired a new position in Enovis during the fourth quarter worth about $1,998,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ENOV has been the subject of a number of research reports. BTIG Research boosted their target price on shares of Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday. Canaccord Genuity Group lowered their target price on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 target price on shares of Enovis in a report on Thursday. Wells Fargo & Company boosted their price target on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Evercore reaffirmed an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $47.43.

Check Out Our Latest Research Report on Enovis

Enovis News Summary

Here are the key news stories impacting Enovis this week:

Positive Sentiment: Q4 adjusted earnings outpaced estimates — Enovis reported adjusted EPS of $0.95 (beat vs. ~$0.81 consensus), signaling underlying operating profitability despite GAAP noise. Enovis (ENOV) Q4 Earnings Beat Estimates
Positive Sentiment: Management raised FY‑2026 EPS guidance to $3.52–3.73, above Street expectations — that upward EPS range supports a higher valuation multiple and helped sentiment. Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
Positive Sentiment: Street support: BTIG boosted its price target and kept a Buy, and a notable fund added ~$5M to a position, both signaling conviction from some investors/analysts. Benzinga (BTIG price target raise) One Fund Bet $5 Million on Enovis Stock Last Quarter. Shares Surged 14% Post‑Earnings
Neutral Sentiment: Top‑line growth mixed: full‑year sales grew ~7% (2H momentum in Reconstructive) and Q4 net sales rose ~3%, showing commercial progress but not a breakout. Enovis Announces Fourth Quarter and Full Year 2025 Results
Neutral Sentiment: Adjusted metrics remain healthier: adjusted EBITDA and adjusted EPS show profitable operations (adjusted EBITDA/adj. EPS materially positive), which the company highlights as the basis for its guidance. QuiverQuant summary of Enovis results
Negative Sentiment: Revenue missed Q4 consensus ($575.8M vs. ~$584M expected) and full‑year revenue guidance (~$2.31–2.37B) sits slightly below some Street views — a headwind for growth expectations. Enovis beats earnings but misses on revenue
Negative Sentiment: Large non‑cash goodwill impairment ($501M Q4, $1.05B FY) produced a substantial GAAP net loss (Q4 and FY), weakening headline earnings, accumulated deficit and some balance‑sheet metrics — a risk for longer‑term investor confidence. QuiverQuant (impairment and GAAP loss details)

Enovis Company Profile

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.